A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Chronic Lymphocytic Leukemia · Waldenstrom Macroglobulinemia · Mantle Cell Lymphoma · Marginal Zone Lymphoma · B-cell Lymphoma · Small Lymphocytic Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jan 2025, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 803 (final count)
- Started
- Mar 15, 2019
- Main results expected
- Jan 27, 2025
- Fully finished
- Dec 23, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose (MTD)
Measured over: Up to 24 Months
Recommended dose for further study
Measured over: Up to 24 Months
To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC).
Measured over: Up to 24 months
To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
Measured over: Up to 24 Months
To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
Measured over: Up to 24 Months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-01-27, no fading
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT03740529 · record last updated 2026-01-27 · checked 2026-11-09 15:36 UTC